Apria, Inc. (NYSE:APR) SVP Celina M. Scally sold 1,278 shares of the firm’s stock in a transaction on Wednesday, October 13th. The stock was sold at an average price of $32.35, for a total value of $41,343.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
NYSE:APR opened at $32.41 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.21 and a debt-to-equity ratio of 215.95. The stock’s 50-day simple moving average is $35.52 and its 200 day simple moving average is $31.21. Apria, Inc. has a 52-week low of $20.07 and a 52-week high of $40.00.
Apria (NYSE:APR) last released its earnings results on Thursday, August 5th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The company had revenue of $286.28 million during the quarter, compared to analyst estimates of $280.18 million. On average, analysts expect that Apria, Inc. will post 1.63 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC acquired a new stake in shares of Apria in the second quarter valued at about $28,000. UBS Group AG acquired a new position in Apria during the first quarter worth approximately $78,000. JPMorgan Chase & Co. acquired a new position in Apria during the first quarter worth approximately $79,000. New York State Common Retirement Fund acquired a new position in Apria during the first quarter worth approximately $95,000. Finally, American International Group Inc. acquired a new position in Apria during the first quarter worth approximately $123,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.
Apria, Inc provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products.
Recommended Story: Understanding Relative Strength Index
Receive News & Ratings for Apria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apria and related companies with MarketBeat.com's FREE daily email newsletter.